Incyte

INCY · NASDAQ

$116.62+$3.37 (+2.97%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $113.25

Latest news

Press releaseOct 18, 6:05 PM ETBusiness Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
NewsOct 15, 2:06 PM ETVandana Singh
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Press releaseOct 8, 8:00 AM ETBusiness Wire
Incyte to Report Third Quarter Financial Results
Press releaseOct 6, 7:35 AM ETGlobe Newswire
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
NewsSep 28, 12:54 PM ETVandana Singh
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
Press releaseSep 28, 9:03 AM ETPRNewswire
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
NewsSep 28, 8:38 AM ETVandana Singh
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
Press releaseSep 25, 7:00 PM ETBusiness Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
NewsSep 25, 2:53 PM ET
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
NewsSep 22, 8:36 AM ET
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Press releaseSep 22, 8:30 AM ETBusiness Wire
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
NewsSep 21, 2:26 AM ET
Reported Sunday, Specialised Therapeutics To Commercialise, Distribute And Register Incyte's Ruxolitinib Cream (Opzelura) In Australia, Expects To Progress Regulatory And Reimbursement Submissions
Press releaseSep 20, 4:00 PM ETPRNewswire
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
NewsSep 17, 7:31 AM ETAvi Kapoor
Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’
NewsSep 16, 1:38 PM ETVandana Singh
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Press releaseSep 1, 8:00 AM ETBusiness Wire
Incyte to Present at Upcoming Investor Conferences
Press releaseAug 27, 6:00 PM ETGlobe Newswire
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
Press releaseAug 7, 4:30 PM ETBusiness Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 2, 10:01 AM ETPRNewswire
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
NewsJul 29, 10:53 AM ETAvi Kapoor
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
NewsJul 29, 8:45 AM ETAvi Kapoor
Top 3 Health Care Stocks That May Implode This Month
Press releaseJul 29, 6:00 AM ETBusiness Wire
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
NewsJul 28, 3:10 PM ETVandana Singh
Incyte Says It's No Longer A One-Drug Story
NewsJul 28, 8:18 AM ETAvi Kapoor
ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’
NewsJul 28, 7:02 AM ET
Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate
Press releaseJul 28, 7:00 AM ETBusiness Wire
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Press releaseJul 20, 8:00 AM ETPRNewswire
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Press releaseJul 17, 1:10 PM ETBusiness Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
NewsJul 13, 9:25 AM ETVandana Singh
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Press releaseJul 13, 4:00 AM ETBusiness Wire
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Press releaseJul 8, 8:00 AM ETBusiness Wire
Incyte to Report Second Quarter Financial Results
Press releaseJul 6, 8:39 AM ETBusiness Wire
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Press releaseJun 26, 9:00 AM ETBusiness Wire
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Press releaseJun 26, 7:30 AM ETBusiness Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Press releaseJun 19, 2:00 AM ETBusiness Wire
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Press releaseJun 14, 4:35 PM ETBusiness Wire
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Press releaseJun 13, 11:15 AM ETBusiness Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
NewsApr 28, 7:36 AM ET
CORRECTION: Incyte Q1 Adj. EPS $1.81 Beats $1.37 Estimate, Sales $1.273B Beat $1.217B Estimate.
NewsApr 28, 7:11 AM ET
Earnings Scheduled For April 28, 2026
NewsMar 9, 8:00 AM ET
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts
NewsFeb 10, 7:02 AM ET
Earnings Breakdown: Incyte Q4
NewsAug 1, 9:31 AM ETAvi Kapoor
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Incyte to Report Third Quarter Financial Results

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily

Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Reported Sunday, Specialised Therapeutics To Commercialise, Distribute And Register Incyte's Ruxolitinib Cream (Opzelura) In Australia, Expects To Progress Regulatory And Reimbursement Submissions

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

Incyte to Present at Upcoming Investor Conferences

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Top 3 Health Care Stocks That May Implode This Month

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Incyte Says It's No Longer A One-Drug Story

ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’

Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte to Report Second Quarter Financial Results

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

CORRECTION: Incyte Q1 Adj. EPS $1.81 Beats $1.37 Estimate, Sales $1.273B Beat $1.217B Estimate.

Earnings Scheduled For April 28, 2026

A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts

Earnings Breakdown: Incyte Q4

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday